{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:38Z","timestamp":1787037998301,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Renji Infection Control Program","award":["RJIPC2025003"],"award-info":[{"award-number":["RJIPC2025003"]}]},{"name":"Shanghai Science and Technology Program Project","award":["25SF1901300, 25SF1901301"],"award-info":[{"award-number":["25SF1901300, 25SF1901301"]}]},{"name":"Shanghai Young Pharmaceutical Talents Capacity Building Program","award":["SPAQNRC2025A07"],"award-info":[{"award-number":["SPAQNRC2025A07"]}]},{"name":"\u201cScientific Benchmarking Management of Antimicrobial Drugs\u201d Project established by Clinical Pharmacy Management Professional Committee of Shanghai Hospital Association","award":["2023LCYS001_S08"],"award-info":[{"award-number":["2023LCYS001_S08"]}]},{"name":"Shanghai Hospital Development Center Foundation","award":["SHDC12024630"],"award-info":[{"award-number":["SHDC12024630"]}]},{"name":"Youth Research Promotion Program of Ren Ji Hospital","award":["RJTJ25-QN-122"],"award-info":[{"award-number":["RJTJ25-QN-122"]}]},{"name":"the Academic leader training program of Pudong New Area Health Commission","award":["PWRd2023-02"],"award-info":[{"award-number":["PWRd2023-02"]}]},{"name":"the Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department","award":["CPA-Z05-ZC-2023-003"],"award-info":[{"award-number":["CPA-Z05-ZC-2023-003"]}]},{"name":"Shanghai \u201cRising Stars of Medical Talents\u201d Youth Development Program","award":["JL"],"award-info":[{"award-number":["JL"]}]},{"name":"the Clinical Research Innovation and Cultivation Fund of Ren Ji hospital","award":["PY2018-III-04"],"award-info":[{"award-number":["PY2018-III-04"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22137006"],"award-info":[{"award-number":["22137006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00228-026-04130-7","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:43:28Z","timestamp":1783651408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infection risks associated with b\/tsDMARDs in rheumatoid arthritis: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4897-1103","authenticated-orcid":false,"given":"Xue-Mei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Dan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zai-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Jia","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"1","key":"4130_CR1","doi-asserted-by":"publisher","first-page":"Itc1","DOI":"10.7326\/aitc201901010","volume":"170","author":"JA Sparks","year":"2019","unstructured":"Sparks JA (2019) Rheumatoid arthritis [J]. Ann Intern Med 170(1):Itc1-itc16. https:\/\/doi.org\/10.7326\/aitc201901010","journal-title":"Ann Intern Med"},{"issue":"6","key":"4130_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Longo DL, Firestein GS (2023) Rheumatoid arthritis \u2014 common origins, divergent mechanisms[J]. N Engl J Med 388(6):529\u2013542. https:\/\/doi.org\/10.1056\/NEJMra2103726","journal-title":"N Engl J Med"},{"issue":"7","key":"4130_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis[J]. Arthritis Care Res (Hoboken) 73(7):924\u2013939. https:\/\/doi.org\/10.1002\/acr.24596","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"4130_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2022) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update[J]. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4130_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard-2022-223357","volume":"82","author":"A Sepriano","year":"2022","unstructured":"Sepriano A, Kerschbaumer A, Bergstra SA et al (2022) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis[J]. Ann Rheum Dis 82(1):107\u2013118. https:\/\/doi.org\/10.1136\/ard-2022-223357","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4130_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2012","unstructured":"Listing J, Gerhold K, Zink A (2012) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment[J]. Rheumatology 52(1):53\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kes305","journal-title":"Rheumatology"},{"issue":"19","key":"4130_CR7","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials[J]. JAMA 295(19):2275\u20132285. https:\/\/doi.org\/10.1001\/jama.295.19.2275","journal-title":"JAMA"},{"issue":"9990","key":"4130_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/s0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis[J]. Lancet 386(9990):258\u2013265. https:\/\/doi.org\/10.1016\/s0140-6736(14)61704-9","journal-title":"Lancet"},{"key":"4130_CR9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews[J]. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"11","key":"4130_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations[J]. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/m14-2385","journal-title":"Ann Intern Med"},{"issue":"9","key":"4130_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis 69(9):1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4130_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1987","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1987) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum 31(3):315\u2013324. https:\/\/doi.org\/10.1002\/art.1780310302","journal-title":"Arthritis Rheum"},{"key":"4130_CR13","doi-asserted-by":"publisher","first-page":"I4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials[J]. BMJ 366:I4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"4","key":"4130_CR14","doi-asserted-by":"publisher","first-page":"e002262","DOI":"10.1136\/bmjsem-2024-002262","volume":"10","author":"DL Belav\u00fd","year":"2024","unstructured":"Belav\u00fd DL, Kaczorowski S, Saueressig T et al (2024) How to conduct and report checking transitivity and inconsistency in network-meta-analysis: a narrative review including practical worked examples, code and source data for sports and exercise medicine researchers[J]. BMJ Open Sport Exerc Med 10(4):e002262. https:\/\/doi.org\/10.1136\/bmjsem-2024-002262","journal-title":"BMJ Open Sport Exerc Med"},{"issue":"4","key":"4130_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial[J]. Evid Based Ment Health 22(4):153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"4130_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, Schwarzer G (2023) netmeta: An R Package for network meta-analysis using frequentist methods[J]. J Stat Softw 106:1\u201340. https:\/\/doi.org\/10.18637\/jss.v106.i02","journal-title":"J Stat Softw"},{"issue":"8","key":"4130_CR17","doi-asserted-by":"publisher","first-page":"e010983","DOI":"10.1136\/bmjopen-2015-010983","volume":"6","author":"J Cheng","year":"2016","unstructured":"Cheng J, Pullenayegum E, Marshall JK et al (2016) Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study[J]. BMJ Open 6(8):e010983. https:\/\/doi.org\/10.1136\/bmjopen-2015-010983","journal-title":"BMJ Open"},{"issue":"1","key":"4130_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s2215-0366(19)30416-x","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis[J]. Lancet Psychiatry 7(1):64\u201377. https:\/\/doi.org\/10.1016\/s2215-0366(19)30416-x","journal-title":"Lancet Psychiatry"},{"issue":"sep24 5","key":"4130_CR19","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Schunemann HJ, Murad MH et al (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis[J]. BMJ 349(sep24 5):g5630\u2013g5630. https:\/\/doi.org\/10.1136\/bmj.g5630","journal-title":"BMJ"},{"key":"4130_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE et al (2018) Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis[J]. J Clin Epidemiol 93:36\u201344. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.10.005","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"4130_CR21","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"AR Balanescu","year":"2022","unstructured":"Balanescu AR, Citera G, Pascual-Ramos V et al (2022) Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial[J]. Ann Rheum Dis 81(11):1491\u20131503. https:\/\/doi.org\/10.1136\/ard-2022-222405","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4130_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J et al (2015) Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials[J]. Arthritis Res Ther 17(1):362. https:\/\/doi.org\/10.1186\/s13075-015-0880-2","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"4130_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/acr2.11064","volume":"1","author":"G Ozen","year":"2019","unstructured":"Ozen G, Pedro S, England BR et al (2019) Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease\u2010modifying antirheumatic drugs[J]. ACR Open Rheumatol 1(7):424\u2013432. https:\/\/doi.org\/10.1002\/acr2.11064","journal-title":"ACR Open Rheumatol"},{"issue":"7","key":"4130_CR24","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.4103\/jfmpc.jfmpc_2147_21","volume":"11","author":"P Gupta","year":"2022","unstructured":"Gupta P, Padhan P, Bhargava N et al (2022) Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs[J]. J Family Med Prim Care 11(7):3575\u20133583. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2147_21","journal-title":"J Family Med Prim Care"},{"key":"4130_CR25","doi-asserted-by":"publisher","first-page":"103488","DOI":"10.1016\/j.eclinm.2025.103488","volume":"88","author":"R Xiao","year":"2025","unstructured":"Xiao R, Tang P, Zhou J et al (2025) Safety of TNF-\u03b1 inhibitors therapy in patients with rheumatoid arthritis: an umbrella review[J]. eClinicalMedicine 88:103488. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103488","journal-title":"eClinicalMedicine"},{"issue":"10","key":"4130_CR26","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/art.41754","volume":"73","author":"K Bechman","year":"2021","unstructured":"Bechman K, Halai K, Yates M et al (2021) Nonserious infections in patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis[J]. Arthritis Rheumatol 73(10):1800\u20131809. https:\/\/doi.org\/10.1002\/art.41754","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"4130_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z, Buch MH, Charles-Schoeman C et al (2024) Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician[J]. Nat Rev Rheumatol 20(2):101\u2013115. https:\/\/doi.org\/10.1038\/s41584-023-01062-9","journal-title":"Nat Rev Rheumatol"},{"issue":"9865","key":"4130_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s0140-6736(12)61424-x","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial[J]. Lancet 381(9865):451\u2013460. https:\/\/doi.org\/10.1016\/s0140-6736(12)61424-x","journal-title":"Lancet"},{"issue":"10093","key":"4130_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/s0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial[J]. Lancet 390(10093):457\u2013468. https:\/\/doi.org\/10.1016\/s0140-6736(17)31618-5","journal-title":"Lancet"},{"issue":"6","key":"4130_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis[J]. N Engl J Med 367(6):495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071","journal-title":"N Engl J Med"},{"issue":"4","key":"4130_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial[J]. Ann Intern Med 159(4):253\u2013261. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00006","journal-title":"Ann Intern Med"},{"issue":"25","key":"4130_CR32","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis[J]. N Engl J Med 370(25):2377\u20132386. https:\/\/doi.org\/10.1056\/NEJMoa1310476","journal-title":"N Engl J Med"},{"issue":"1","key":"4130_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen Y-C et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study[J]. Ann Rheum Dis 76(1):88\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210094","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4130_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment[J]. Arthritis Rheumatol 69(3):506\u2013517. https:\/\/doi.org\/10.1002\/art.39953","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"4130_CR35","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O et al (2016) Baricitinib in Patients with Refractory Rheumatoid Arthritis[J]. N Engl J Med 374(13):1243\u20131252. https:\/\/doi.org\/10.1056\/NEJMoa1507247","journal-title":"N Engl J Med"},{"issue":"4","key":"4130_CR36","first-page":"732","volume":"38","author":"Z Li","year":"2020","unstructured":"Li Z, Hu J, Bao C et al (2020) Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study[J]. Clin Exp Rheumatol 38(4):732\u2013741","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"4130_CR37","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D et al (2017) Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis[J]. N Engl J Med 376(7):652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"issue":"10139","key":"4130_CR38","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/s0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F et al (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet 391(10139):2503\u20132512. https:\/\/doi.org\/10.1016\/s0140-6736(18)31115-2","journal-title":"Lancet"},{"issue":"11","key":"4130_CR39","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH et al (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial[J]. Arthritis & Rheumatology 71(11):1788\u20131800. https:\/\/doi.org\/10.1002\/art.41032","journal-title":"Arthritis & Rheumatology"},{"issue":"10139","key":"4130_CR40","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/s0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial[J]. Lancet 391(10139):2513\u20132524. https:\/\/doi.org\/10.1016\/s0140-6736(18)31116-4","journal-title":"Lancet"},{"issue":"11","key":"4130_CR41","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","volume":"59","author":"H Kameda","year":"2020","unstructured":"Kameda H, Takeuchi T, Yamaoka K et al (2020) Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study[J]. Rheumatology (Oxford) 59(11):3303\u20133313. https:\/\/doi.org\/10.1093\/rheumatology\/keaa084","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"4130_CR42","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL et al (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis[J]. N Engl J Med 383(16):1511\u20131521. https:\/\/doi.org\/10.1056\/NEJMoa2008250","journal-title":"N Engl J Med"},{"issue":"10188","key":"4130_CR43","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/s0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study[J]. Lancet 393(10188):2303\u20132311. https:\/\/doi.org\/10.1016\/s0140-6736(19)30419-2","journal-title":"Lancet"},{"issue":"10","key":"4130_CR44","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL et al (2020) Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial[J]. Arthritis Rheumatol 72(10):1607\u20131620. https:\/\/doi.org\/10.1002\/art.41384","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"4130_CR45","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y et al (2021) Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial[J]. Ann Rheum Dis 80(7):848\u2013858. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219214","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4130_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg J-E et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy[J]. JAMA 322(4):315\u2013325. https:\/\/doi.org\/10.1001\/jama.2019.9055","journal-title":"JAMA"},{"issue":"6","key":"4130_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","volume":"80","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Rigby WFC, van der Heijde D et al (2021) Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial[J]. Ann Rheum Dis 80(6):727\u2013738. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219213","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4130_CR48","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Iwasaki M et al (2016) Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study[J]. Ann Rheum Dis 75(6):1057\u20131064. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208279","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4130_CR49","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Tanaka S et al (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan[J]. Ann Rheum Dis 78(10):1305\u20131319. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215164","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4130_CR50","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","volume":"78","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Takeuchi T, Tanaka S et al (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)[J]. Ann Rheum Dis 78(10):1320\u20131332. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215163","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4130_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T et al (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement[J]. Ann Rheum Dis 80(1):71\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218398","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"4130_CR52","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.3390\/jcm11154459","volume":"11","author":"F Wang","year":"2022","unstructured":"Wang F, Tang X, Zhu M et al (2022) Efficacy and safety of JAK inhibitors for rheumatoid arthritis: a meta-analysis[J]. J Clin Med 11(15):4459. https:\/\/doi.org\/10.3390\/jcm11154459","journal-title":"J Clin Med"},{"issue":"2","key":"4130_CR53","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1097\/rhu.0000000000001749","volume":"28","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D et al (2022) The risk of infections associated with JAK inhibitors in rheumatoid arthritis[J]. J Clin Rheumatol 28(2):e407\u2013e414. https:\/\/doi.org\/10.1097\/rhu.0000000000001749","journal-title":"J Clin Rheumatol"},{"key":"4130_CR54","doi-asserted-by":"publisher","first-page":"977265","DOI":"10.3389\/fimmu.2022.977265","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Yan Y-D, Shi F-H et al (2022) Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: a systematic review and meta-analysis[J]. Front Immunol 13:977265. https:\/\/doi.org\/10.3389\/fimmu.2022.977265","journal-title":"Front Immunol"},{"issue":"7","key":"4130_CR55","doi-asserted-by":"publisher","first-page":"e0306548","DOI":"10.1371\/journal.pone.0306548","volume":"19","author":"K Ouranos","year":"2024","unstructured":"Ouranos K, Avila DV, Mylona EK et al (2024) Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: a systematic review and meta-analysis[J]. PLoS ONE 19(7):e0306548. https:\/\/doi.org\/10.1371\/journal.pone.0306548","journal-title":"PLoS ONE"},{"issue":"8","key":"4130_CR56","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2217\/imt-2018-0178","volume":"11","author":"J Jegatheeswaran","year":"2019","unstructured":"Jegatheeswaran J, Turk M, Pope JE (2019) Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review[J]. Immunotherapy 11(8):737\u2013754. https:\/\/doi.org\/10.2217\/imt-2018-0178","journal-title":"Immunotherapy"},{"issue":"8","key":"4130_CR57","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","volume":"79","author":"YH Lee","year":"2020","unstructured":"Lee YH, Song GG (2020) Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis[J]. Z Rheumatol 79(8):785\u2013796. https:\/\/doi.org\/10.1007\/s00393-020-00750-1","journal-title":"Z Rheumatol"},{"issue":"5","key":"4130_CR58","doi-asserted-by":"publisher","first-page":"835","DOI":"10.11124\/jbies-22-00048","volume":"21","author":"K Makimoto","year":"2023","unstructured":"Makimoto K, Konno R, Kinoshita A et al (2023) Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review[J]. JBI Evid Synth 21(5):835\u2013885. https:\/\/doi.org\/10.11124\/jbies-22-00048","journal-title":"JBI Evid Synth"},{"issue":"9","key":"4130_CR59","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.55563\/clinexprheumatol\/f7ff6q","volume":"40","author":"C Specker","year":"2022","unstructured":"Specker C, Aringer M, Burmester GR et al (2022) The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age[J]. Clin Exp Rheumatol 40(9):1657\u20131665. https:\/\/doi.org\/10.55563\/clinexprheumatol\/f7ff6q","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"4130_CR60","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3899\/jrheum.2022-1283","volume":"50","author":"L Bessette","year":"2023","unstructured":"Bessette L, Rahman P, Kelsall J et al (2023) Real-world incidence and determinants of infection in patients with rheumatoid arthritis treated with golimumab after a median follow-up time of 27 months[J]. J Rheumatol 50(9):1121\u20131126. https:\/\/doi.org\/10.3899\/jrheum.2022-1283","journal-title":"J Rheumatol"},{"issue":"4","key":"4130_CR61","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.22504","volume":"56","author":"JR Curtis","year":"2007","unstructured":"Curtis JR, Patkar N, Xie A et al (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor \u03b1 antagonists[J]. Arthritis Rheum 56(4):1125\u20131133. https:\/\/doi.org\/10.1002\/art.22504","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4130_CR62","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/acr.24984","volume":"75","author":"H Yun","year":"2023","unstructured":"Yun H, Chen L, Roy JA et al (2023) Rheumatoid arthritis disease activity and hospitalized infection in a large US registry[J]. Arthritis Care Res 75(8):1639\u20131647. https:\/\/doi.org\/10.1002\/acr.24984","journal-title":"Arthritis Care Res"},{"issue":"10","key":"4130_CR63","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/art.41754","volume":"73","author":"K Bechman","year":"2021","unstructured":"Bechman K, Halai K, Yates M et al (2021) Nonserious infections in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis[J]. Arthritis Rheumatol 73(10):1800\u20131809. https:\/\/doi.org\/10.1002\/art.41754","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4130_CR64","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/acr.25282","volume":"76","author":"N Singh","year":"2024","unstructured":"Singh N, Gold LS, Lee J et al (2024) Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted\u2010synthetic disease\u2010modifying antirheumatic drugs[J]. Arthritis Care Res 76(5):627\u2013635. https:\/\/doi.org\/10.1002\/acr.25282","journal-title":"Arthritis Care Res"},{"issue":"8","key":"4130_CR65","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/acr.25117","volume":"75","author":"BR England","year":"2022","unstructured":"England BR, Smith BJ, Baker NA et al (2022) 2022 American College of Rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis[J]. Arthritis Care Res 75(8):1603\u20131615. https:\/\/doi.org\/10.1002\/acr.25117","journal-title":"Arthritis Care Res"},{"issue":"1","key":"4130_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2019","unstructured":"Furer V, Rondaan C, Heijstek MW et al (2019) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J]. Ann Rheum Dis 79(1):39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4130_CR67","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/rhu.0000000000000731","volume":"24","author":"K Yukawa","year":"2018","unstructured":"Yukawa K, Nagamoto Y, Watanabe H et al (2018) Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole[J]. J Clin Rheumatol 24(7):355\u2013360. https:\/\/doi.org\/10.1097\/rhu.0000000000000731","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"4130_CR68","first-page":"862","volume":"37","author":"A Doria","year":"2019","unstructured":"Doria A, Zavaglia D (2019) Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review[J]. Clin Exp Rheumatol 37(5):862\u2013871","journal-title":"Clin Exp Rheumatol"},{"issue":"16","key":"4130_CR69","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1002\/sim.8158","volume":"38","author":"O Efthimiou","year":"2019","unstructured":"Efthimiou O, R\u00fccker G, Schwarzer G et al (2019) Network meta\u2010analysis of rare events using the Mantel\u2010Haenszel method[J]. Stat Med 38(16):2992\u20133012. https:\/\/doi.org\/10.1002\/sim.8158","journal-title":"Stat Med"},{"issue":"1","key":"4130_CR70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA et al (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events[J]. Stat Med 26(1):53\u201377. https:\/\/doi.org\/10.1002\/sim.2528","journal-title":"Stat Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04130-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:22Z","timestamp":1787036122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04130-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04130-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"200"}}